512 related articles for article (PubMed ID: 28208660)
1. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
2. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.
Taruneshwar Jha K; Shome A; Chahat ; Chawla PA
Bioorg Chem; 2023 Sep; 138():106680. PubMed ID: 37336103
[TBL] [Abstract][Full Text] [Related]
4. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
Ghosh S; Marrocco I; Yarden Y
Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
[TBL] [Abstract][Full Text] [Related]
5. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.
Huang XL; Khan MI; Wang J; Ali R; Ali SW; Zahra QU; Kazmi A; Lolai A; Huang YL; Hussain A; Bilal M; Li F; Qiu B
Int J Biol Macromol; 2021 Jun; 180():739-752. PubMed ID: 33737188
[TBL] [Abstract][Full Text] [Related]
6. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
7. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
8. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer.
Donzelli S; Cioce M; Muti P; Strano S; Yarden Y; Blandino G
Semin Cell Dev Biol; 2016 Feb; 50():133-42. PubMed ID: 26773212
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.
Chen MK; Hung MC
FEBS J; 2015 Oct; 282(19):3693-721. PubMed ID: 26096795
[TBL] [Abstract][Full Text] [Related]
11. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
12. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
13. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
Tolmachev V; Stone-Elander S; Orlova A
Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
[TBL] [Abstract][Full Text] [Related]
14. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
15. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
[TBL] [Abstract][Full Text] [Related]
16. Adaptive responses to antibody based therapy.
Rodems TS; Iida M; Brand TM; Pearson HE; Orbuch RA; Flanigan BG; Wheeler DL
Semin Cell Dev Biol; 2016 Feb; 50():153-63. PubMed ID: 26808665
[TBL] [Abstract][Full Text] [Related]
17. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of receptor tyrosine kinase activation in cancer.
Du Z; Lovly CM
Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
[TBL] [Abstract][Full Text] [Related]
19. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases.
Shimizu M; Adachi S; Masuda M; Kozawa O; Moriwaki H
Mol Nutr Food Res; 2011 Jun; 55(6):832-43. PubMed ID: 21538846
[TBL] [Abstract][Full Text] [Related]
20. RTKs in pathobiology of head and neck cancers.
Nadhan R; Srinivas P; Pillai MR
Adv Cancer Res; 2020; 147():319-373. PubMed ID: 32593405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]